Renal Toxicity

Maen Abdelrahim; Ala Abudayyeh

doi:10.1007/978-3-030-79308-1_16

Renal Toxicity

Adv Exp Med Biol. 2021:1342:389-397. doi: 10.1007/978-3-030-79308-1_16.

Authors

Maen Abdelrahim¹, Ala Abudayyeh²

Affiliations

¹ Institute of Academic Medicine and Weill Cornell Medical College, Houston Methodist Cancer Center, Houston Methodist Cancer Center, Houston, TX, USA.
² Division of Internal Medicine, Section of Nephrology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. aabudayyeh@mdanderson.org.

PMID: 34972976
DOI: 10.1007/978-3-030-79308-1_16

Abstract

With the increasing use of immunotherapy, there has been an associated increased survival in many cancers but has also resulted in unregulated organ-specific toxicities. In this review, we will discuss the renal toxicities associated with a checkpoint inhibitor (CPI) from the typical acute tubulointerstitial nephritis to glomerulonephritis and their proposed mechanisms and treatments. We also discuss the use of CPI and reactivation of preexisting autoimmune disease with a focus on renal cell cancer in setting of chronic kidney disease (CKD). Transplant rejection in setting of CPI use has been further evaluated with single-center and multicenter retrospective studies, and available data will be presented in this chapter.

Keywords: Acute interstitial nephritis; Autoimmune disease induction; Immune-related adverse events; Organ transplant rejection; Renal cell cancer.

Publication types

Review

MeSH terms

Humans
Immunotherapy
Multicenter Studies as Topic
Neoplasms*
Nephritis, Interstitial*
Renal Insufficiency, Chronic*
Retrospective Studies